Timothy B Niewold

Oct 4, 2024 | healio.com | Rob Volansky |Shenaz Bagha |Deepak Rao |Timothy B Niewold

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A recent investigation into the molecular roots of systemic lupus erythematosus may point the way toward a new generation of therapeutic targets, according to the researchers.

Feb 27, 2024 | nature.com | Timothy B Niewold

AbstractIn genomic medicine, the concept of genetically transitional disease (GTD) refers to cases in which gene mutation is necessary but not sufficient to cause disease. In this Perspective, we apply this novel concept to rheumatic diseases, which have been linked to hundreds of genetic variants via association studies. These variants are in the ‘grey zone’ between monogenic variants with large effect sizes and common susceptibility alleles with small effect sizes.